Peer-influenced content. Sources you trust. No registration required. This is HCN.
Pulmonology Advisor
The GINA 2026 update introduces age-stratified primary care flowcharts for asthma exacerbation management, expands biologic guidance including depemokimab, and adds a formal red-flag list for fatal or near-fatal asthma risk in adults and adolescents.
Adolescent Medicine June 17th 2026
A DNA methylation–based IgE score measured in infancy was associated with recurrent wheezing by age 3 across three pediatric cohorts.
Allergy & Immunology May 7th 2026
Annals of Internal Medicine
The working group strongly recommended inhaled corticosteroids (ICS) and streamlined management of asthma by suggesting a combination of ICS and rapid-onset long-acting β-agonist as both reliever and controller agents and step-up therapy by increasing ICS and/or adding long-acting anticholinergic agents.
Allergy & Immunology March 16th 2026
Consultant360
“Today’s approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment.” – Iilun Murphy, MD, Director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research
Allergy & Immunology March 12th 2026
WebMD
In pregnancy, asthma effects vary significantly: one-third of patients experience worsening symptoms, one-third improve, and one-third remain stable. Properly controlled asthma during pregnancy does not increase maternal or infant complications.
Allergy & Immunology January 9th 2025
Prescription medications for smoking cessation demonstrate 2-3 times greater effectiveness compared to nicotine gum, offering a superior intervention option for asthma patients who smoke.
Allergy & Immunology December 5th 2024